Bank of New York Mellon’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.46M | Buy |
109,349
+11,594
| +12% | +$155K | ﹤0.01% | 2890 |
|
|
2025
Q1 | $996K | Sell |
97,755
-123
| -0.1% | -$1.25K | ﹤0.01% | 3060 |
|
|
2024
Q4 | $1.55M | Buy |
97,878
+2,462
| +3% | +$39K | ﹤0.01% | 2869 |
|
|
2024
Q3 | $5.54M | Sell |
95,416
-22,972
| -19% | -$1.33M | ﹤0.01% | 2246 |
|
|
2024
Q2 | $5.41M | Buy |
118,388
+18,755
| +19% | +$857K | ﹤0.01% | 2306 |
|
|
2024
Q1 | $6.6M | Buy |
99,633
+5,129
| +5% | +$340K | ﹤0.01% | 2180 |
|
|
2023
Q4 | $3.76M | Sell |
94,504
-49,905
| -35% | -$1.98M | ﹤0.01% | 2510 |
|
|
2023
Q3 | $4.6M | Buy |
144,409
+42,771
| +42% | +$1.36M | ﹤0.01% | 2357 |
|
|
2023
Q2 | $4.08M | Sell |
101,638
-30,939
| -23% | -$1.24M | ﹤0.01% | 2434 |
|
|
2023
Q1 | $5.66M | Buy |
132,577
+38,650
| +41% | +$1.65M | ﹤0.01% | 2232 |
|
|
2022
Q4 | $4.51M | Buy |
93,927
+19,410
| +26% | +$932K | ﹤0.01% | 2395 |
|
|
2022
Q3 | $2.8M | Buy |
74,517
+27,744
| +59% | +$1.04M | ﹤0.01% | 2620 |
|
|
2022
Q2 | $1.29M | Buy |
46,773
+321
| +0.7% | +$8.87K | ﹤0.01% | 3075 |
|
|
2022
Q1 | $2.53M | Buy |
46,452
+152
| +0.3% | +$8.27K | ﹤0.01% | 2806 |
|
|
2021
Q4 | $2.71M | Buy |
46,300
+3,345
| +8% | +$196K | ﹤0.01% | 2806 |
|
|
2021
Q3 | $1.7M | Buy |
42,955
+4,595
| +12% | +$182K | ﹤0.01% | 3085 |
|
|
2021
Q2 | $1.63M | Sell |
38,360
-4,369
| -10% | -$186K | ﹤0.01% | 3133 |
|
|
2021
Q1 | $2.63M | Sell |
42,729
-124
| -0.3% | -$7.63K | ﹤0.01% | 2766 |
|
|
2020
Q4 | $3.02M | Buy |
42,853
+24,748
| +137% | +$1.75M | ﹤0.01% | 2604 |
|
|
2020
Q3 | $699K | Sell |
18,105
-85
| -0.5% | -$3.28K | ﹤0.01% | 3318 |
|
|
2020
Q2 | $682K | Buy |
+18,190
| New | +$682K | ﹤0.01% | 3310 |
|